The hormone that inspired one of the biggest drug classes of the decade barely survives in human circulation.
Natural glucagon-like peptide-1, or GLP-1, is rapidly broken down by an enzyme, giving the active hormone a circulating half-life of approximately one to two minutes. That made it an attractive biological signal but a difficult starting point for a practical medicine.
Semaglutide, the active ingredient in Ozempic and Wegovy, has an elimination half-life of approximately one week.
The semaglutide half life is not an accident of nature. It is the result of three deliberate chemical modifications and a carefully engineered interaction with albumin, the most abundant protein in human blood plasma.
Understanding those changes helps explain why injected semaglutide can be administered weekly, why the medicine remains in circulation for weeks after treatment stops, and why peptide developers continue searching for ways to extend drug action.
The story begins with a hormone the body is designed to eliminate quickly.
A Hormone Built to Disappear
GLP-1 is released by specialized intestinal cells in response to food. It helps regulate glucose-dependent insulin secretion, influences gastric emptying and participates in signaling pathways involved in appetite and energy balance.
Its brief biological lifetime suits a hormone that participates in rapidly changing metabolic responses.
For drug developers, however, that short lifetime created a major obstacle.
In a 1995 study published in the Journal of Clinical Endocrinology and Metabolism, Carolyn Deacon, Anders H. Johnsen and Jens Juul Holst investigated how human plasma breaks down active GLP-1.
They found that the active peptide was converted into an N-terminally truncated metabolite with a half-life of approximately 20.4 minutes when studied in isolated human plasma at 37 degrees Celsius.
That measurement is important, but it must not be confused with the hormone’s lifetime in the body.
The approximately 20-minute figure describes degradation in a laboratory plasma preparation. In living circulation, active native GLP-1 has a much shorter half-life, generally estimated at approximately one to two minutes.
The difference reflects the additional processes involved in circulating hormone breakdown and clearance.
Deacon and colleagues identified dipeptidyl peptidase-IV, now generally called DPP-4, as a central enzyme responsible for GLP-1 degradation.
Inhibiting DPP-4 prevented formation of the truncated metabolite in their laboratory experiments.
The researchers also detected the metabolite in human circulation, supporting the biological relevance of this pathway.
The discovery helped establish two approaches to drug development: inhibit the enzyme that destroys endogenous GLP-1, or redesign the hormone to make it more resistant to destruction.
DPP-4 inhibitor medicines followed one route. Long-acting GLP-1 receptor agonists followed the other.
Natural GLP-1 delivers a short biological signal. Semaglutide was engineered to maintain therapeutic exposure for approximately a week.
Three Chemical Edits That Changed the Semaglutide Half Life
The molecular engineering behind semaglutide was described in a 2015 Journal of Medicinal Chemistry paper led by Jesper Lau and colleagues at Novo Nordisk.
The researchers aimed to develop a GLP-1 analogue suitable for once-weekly administration by combining resistance to enzymatic degradation with stronger binding to serum albumin.
Semaglutide’s peptide backbone contains two amino-acid substitutions compared with native human GLP-1, together with a fatty-acid modification at a third position.
The first change occurs at position 8, where the natural amino acid alanine is replaced by 2-aminoisobutyric acid, commonly abbreviated Aib.
This modification makes semaglutide resistant to cleavage by DPP-4, protecting a vulnerable region of the molecule that contributes to the extremely short lifetime of natural GLP-1.
The second substitution occurs at position 34, where lysine is replaced by arginine.
This change helps ensure that a fatty-acid modification is attached at the intended lysine position rather than producing unwanted alternative attachment sites.
The third change is the attachment of a C18 fatty di-acid side chain to lysine at position 26 through a chemical linker.
This side chain is central to the molecule’s extended action because it promotes reversible binding to albumin.
These modifications work together. Resistance to DPP-4 helps protect the peptide backbone, while albumin association slows clearance and reduces exposure to certain degradation processes.
The result is a molecule designed not merely to activate a receptor, but to remain available long enough to make sustained treatment practical.
How Albumin Turns a Short-Lived Peptide Into a Long-Acting Medicine
Albumin is an abundant plasma protein that transports fatty acids and participates in the distribution of numerous biological and pharmaceutical molecules.
Semaglutide’s attached fatty-acid chain allows it to associate strongly but reversibly with albumin.
When semaglutide is bound to albumin, its effective molecular complex is much larger than the free peptide alone.
This association reduces renal clearance and provides protection against degradation, helping maintain concentrations in circulation over extended periods.
The interaction is not permanent. Semaglutide exists in a dynamic equilibrium between albumin-bound and unbound forms.
The free drug can interact with GLP-1 receptors, while reversible association with albumin contributes to its prolonged availability.
In its 2015 discovery paper, the Novo Nordisk team reported that semaglutide had approximately threefold lower GLP-1 receptor-binding affinity than liraglutide under the experimental conditions studied, but stronger albumin affinity.
That finding illustrates the molecular trade-offs involved in designing a long-acting drug.
It does not mean semaglutide is clinically less effective than liraglutide. Receptor-binding measurements are only one component of pharmacological activity, and clinical outcomes depend on drug exposure, dosing, receptor activation and other factors.
In Göttingen mini-pigs, the researchers measured a plasma half-life of 46.1 hours after intravenous administration of semaglutide.
That result was an animal pharmacokinetic measurement, not the final human half-life.
The later human evidence established the approximately one-week elimination half-life now described in prescribing information.
The fatty-acid chain does more than modify semaglutide’s structure. It changes how the molecule travels, persists and is cleared from the body.
What the FDA Label Says Happens in Humans
The human pharmacokinetic evidence is summarized in FDA-approved prescribing information for Wegovy.
The label states that semaglutide is extensively bound to plasma albumin, with more than 99% albumin binding.
This strong association contributes to reduced renal clearance and protection from degradation.
Following subcutaneous administration, maximum semaglutide concentrations are generally reached approximately one to three days after a dose.
The elimination half-life is approximately one week.
Because the molecule is cleared gradually, repeated weekly injections can maintain exposure over time rather than requiring administration every few hours.
Semaglutide is primarily eliminated after metabolism involving proteolytic cleavage of its peptide backbone and sequential beta-oxidation of its fatty-acid side chain.
The 2026 prescribing information also makes an important distinction between the drug molecule and its formulation.
Wegovy is available in once-weekly injectable and once-daily oral formulations.
Oral Wegovy tablets contain an absorption-enhancing ingredient called SNAC, which helps semaglutide pass through the gastrointestinal barrier.
Oral bioavailability is much lower than subcutaneous bioavailability, and absorption can vary with administration conditions.
Consequently, the same long-acting molecule can be formulated into products with different administration schedules.
A one-week elimination half-life explains an important part of semaglutide’s pharmacology, but it does not mean every semaglutide formulation must be administered once weekly.
The molecule’s long half-life and the formulation’s absorption characteristics must be considered together.
Why a Long Half-Life Cuts Both Ways
A long elimination half-life offers a practical advantage: sustained drug exposure without requiring frequent injections.
However, the same property means semaglutide cannot be rapidly removed from circulation when treatment stops.
The FDA label states that semaglutide can remain in circulation for approximately five to seven weeks after the last dose.
This prolonged persistence matters when clinicians evaluate adverse reactions, interruptions in treatment and situations requiring medication review.
Gastrointestinal adverse reactions, including nausea, vomiting and diarrhea, are among the known effects of semaglutide treatment.
Because systemic exposure changes gradually, stopping treatment does not necessarily mean drug-related effects immediately disappear.
Gradual dose escalation is therefore an important part of the approved treatment schedules, helping patients adjust to increasing drug exposure.
Individual responses vary, and the clinical management of adverse effects depends on severity, medical history and the specific formulation being used.
Pregnancy planning provides another example of why elimination time matters.
The FDA recommends discontinuing Wegovy at least two months before a planned pregnancy because of semaglutide’s long half-life and potential fetal risk.
That recommendation is based on the prescribing information, not simply on a mathematical estimate of five half-lives.
For readers asking how long semaglutide stays in the body, the most useful answer is that meaningful elimination takes weeks, while individual clinical decisions require more than a general pharmacokinetic rule.
The same chemical design that makes weekly therapy possible also means that changes in treatment exposure occur gradually.
The Race to Engineer Peptides That Last Even Longer
Semaglutide’s albumin-binding strategy became an influential example of how deliberate chemical modification can transform the pharmacology of a peptide.
Tirzepatide also uses fatty-acid-based albumin association to help extend drug exposure, although its molecular structure and receptor activity differ from semaglutide.
Other developers are pursuing different approaches to prolonging peptide action.
Amgen’s investigational MariTide, for example, combines an antibody-based structure with peptide receptor activity and is being studied using less frequent injection schedules.
Antibody-based designs seek to exploit the prolonged circulation of larger biological molecules rather than relying on the same albumin-binding mechanism used by semaglutide.
Meanwhile, oral peptide developers face an additional challenge: achieving sufficient absorption from the gastrointestinal tract while retaining the desired duration of action.
Experimental programs such as GZC8072 and the investigation of once-weekly oral peptide delivery illustrate how researchers are exploring alternative ways to combine long drug exposure with convenient administration.
Other metabolic candidates introduce additional biological targets rather than relying solely on the GLP-1 receptor.
Retatrutide, discussed in our explanation of triple-agonist peptide science, combines activity at GLP-1, GIP and glucagon receptors.
These developments illustrate that the next generation of metabolic medicines is being shaped by several related engineering challenges: receptor activity, duration of exposure, molecular stability, delivery and tolerability.
Longer action is not automatically better.
A medicine that persists for an extended period may offer convenience, but its effects and adverse reactions may also be more difficult to reverse quickly.
The ideal duration depends on the molecule, the disease, the administration method and the patient population being studied.
Semaglutide remains an important example because its development connected relatively small molecular changes with a major transformation in therapeutic practicality.
The work of Deacon, Johnsen, Holst, Lau and their colleagues demonstrated two essential principles: understanding how the body breaks down a hormone can reveal opportunities for drug design, and modifying how a peptide interacts with circulating proteins can substantially change its pharmacokinetics.
A natural hormone that survives only minutes in circulation helped inspire a medicine with an elimination half-life measured in days.
The achievement was not simply making GLP-1 stronger. It was engineering a molecule that could resist rapid degradation, associate with albumin and maintain pharmacologically useful exposure over time.
That is the enduring scientific lesson: in peptide medicine, changing how long a molecule survives can be as consequential as changing what the molecule does.
Sources and Further Reading
- Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. Journal of Clinical Endocrinology and Metabolism, March 1995.
- Deacon CF et al. Both subcutaneously and intravenously administered glucagon-like peptide-1 are rapidly degraded in patients with type 2 diabetes and healthy subjects. Diabetes, September 1995.
- Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 Analogue Semaglutide. Journal of Medicinal Chemistry, September 2015.
- U.S. Food and Drug Administration. Wegovy Prescribing Information, revised March 2026. See sections 8.3, 11 and 12.3 for reproductive considerations, molecular design and pharmacokinetics.
- Physiological Reviews. Proglucagon-Derived Peptides: Human Physiology and Therapeutic Potential. Review of GLP-1 physiology and circulating peptide metabolism.
